Clinical Research Directory

Inclusion Criteria: * Adults aged 18 years or above * Diagnosis of type 2 diabetes at least 6 months * CKD (eGFR by CKD-EPI 25-90 ml/min/1.73m2 with uACR 30 to \<300 mg/g) and/or those with severely elevated albuminuria (uACR 30-5000 mg/g) and eGFR \> 60 ml/min/1.73m2. * Patients should have a serum potassium \<4.8 mmol/l at screening * On SGLT2i (dapagliflozin or empaglifozin) at screening at stable doses for at least 4 weeks. * On ACEi or ARB at maximum tolerated dose per manufacturer's label that did not cause unacceptable side effects * In the opinion of the investigator, absence of any physical limitations, addictive diseases, or underlying medical conditions (including mental health) that may preclude the patient from being a suitable study candidate. Exclusion Criteria: * Type 1 diabetes * Allergy, contraindications or intolerance to ACEi/ARB * Contraindications or intolerance to mineralocorticoid receptor antagonists * Allergy, contraindications to SGLT2is * Currently pregnant or planning pregnancy * HbA1c \>9% at enrolment * Uncontrolled hypertension SBP \> 160mmHg or hypotension \<90 mmHg at enrolment * Concomitant therapy with eplenerone, spironolactone that cannot be discontinued. * History of stroke or worsening heart failure in the past 6 months prior to screening * Diabetic ketoacidosis, hyperosmolar hyperglycaemic state or myocardial infarction in the six months prior to screening * Patients on renal replacement therapy or likely require kidney transplant or dialysis during the study period * On concomitant strong CYP3A4 inhibitors that cannot be discontinued * Adrenal insufficiency * Currently participating in another investigational study protocol where the testing or results may interfere with study compliance, diagnostic results, or data collection. * An identified protected vulnerable patient (including but not limited to those in detention, or a prisoner).